Kassas Ibrahim, Nagy Ahmed, Alonso Alvaro, Akhter Mohammed Waseem, Smith Craig S, Ahmed Mohamed, Hafiz Abdul Moiz, Walker Jennifer, Kakouros Nikolaos
UMass Memorial Medical Center, 55 Lake Ave N, Worcester, MA 01655 USA.
J Invasive Cardiol. 2019 Jul;31(7):E205-E210.
Percutaneous revascularization followed by transcatheter aortic valve replacement (TAVR) has been increasingly utilized as an alternative to surgery in patients with severe aortic stenosis (AS) and coronary artery disease (CAD). In many of these patients, the coronary arteries are severely calcified and may best be treated with atherectomy; however, atherectomy is not routinely performed in severe AS patients due to safety concerns. There is a paucity of data on the safety of orbital atherectomy (OA) in patients with severe AS and concurrent calcific CAD.
We retrospectively analyzed the medical records of all patients with severe AS who underwent OA-facilitated percutaneous coronary intervention (PCI) at our center between September 1, 2015 and November 1, 2018.
Twenty-four patients (mean age, 82.5 ± 7.6 years) were identified. Mean aortic valve area was 0.68 ± 0.26 cm and mean aortic valve gradient was 43 ± 17.7 mm Hg. All PCIs were successful (mean diameter stenosis, 80.8 ± 11%; mean number of passes, 5.3 ± 3.3). Two patients had planned hemodynamic support, with left ventricular assist device and intra-aortic balloon pump; none of the patients required vasopressors during PCI. There was a slight reduction in heart rate during OA (71.6 bpm vs 63.3 bpm; P=.02), with no major procedure-related clinical events. Only 1 patient (4.2%) with pre-existing conduction system disease required transient pacing from his permanent pacemaker during OA. All procedures were completed successfully and there were no periprocedural deaths or clinical myocardial infarctions.
OA-facilitated PCI can be safely performed in patients with severe AS and severely calcified CAD with low risk of complications. There was no significant change in blood pressure and heart rate during OA, with minimal need for temporary pacing.
经皮血管重建术联合经导管主动脉瓣置换术(TAVR)已越来越多地被用作严重主动脉瓣狭窄(AS)和冠状动脉疾病(CAD)患者手术的替代方案。在许多此类患者中,冠状动脉严重钙化,可能最好采用旋切术治疗;然而,由于安全问题,严重AS患者通常不进行旋切术。关于严重AS合并钙化性CAD患者眼眶旋切术(OA)安全性的数据很少。
我们回顾性分析了2015年9月1日至2018年11月1日期间在我们中心接受OA辅助经皮冠状动脉介入治疗(PCI)的所有严重AS患者的病历。
共确定了24例患者(平均年龄82.5±7.6岁)。平均主动脉瓣面积为0.68±0.26平方厘米,平均主动脉瓣压差为43±17.7毫米汞柱。所有PCI均成功(平均直径狭窄80.8±11%;平均通过次数5.3±3.3)。2例患者计划进行血流动力学支持,使用左心室辅助装置和主动脉内球囊泵;PCI期间无患者需要血管升压药。OA期间心率略有下降(71.6次/分对63.3次/分;P=0.02),无重大手术相关临床事件。只有1例(4.2%)原有传导系统疾病的患者在OA期间需要其永久起搏器进行临时起搏。所有手术均成功完成,无围手术期死亡或临床心肌梗死。
OA辅助PCI可安全地应用于严重AS和严重钙化性CAD患者,并发症风险低。OA期间血压和心率无显著变化,临时起搏需求最小。